Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and ...
New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...
A study showed cholesterol-lowering statins do not significantly affect ALS progression or survival. Statin prescriptions for ALS patients should be based on metabolic needs, not ALS diagnosis. More ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results